Document is current
Any future updates will be listed below
-
Authors
Desai, Heta https://orcid.org/0000-0003-4362-1707
Andrews, Katrina H.
Bergersen, Kristina V.
Ofori, Samuel
Yu, Fengchao https://orcid.org/0000-0002-7695-3698
Shikwana, Flowreen
Arbing, Mark A.
Boatner, Lisa M. https://orcid.org/0000-0003-0757-4982
Villanueva, Miranda https://orcid.org/0000-0002-4892-8356
Ung, Nicholas
Reed, Elaine F.
Nesvizhskii, Alexey I. https://orcid.org/0000-0002-2806-7819
Backus, Keriann M. https://orcid.org/0000-0001-8541-1404
-
Funding
Funding for this research was provided by:
Arnold and Mabel Beckman Foundation (Beckman Ynoung Investigator Award)
V Foundation for Cancer Research (V2019-017)
UC | UCLA | Jonsson Comprehensive Cancer Center (Seed Grant)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM136614, R01-GM094231)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24-CA271037)
U.S. Department of Energy (DE-FC02-02ER63421)
- License Information
-
More Information
Article History
Received: 28 August 2023
Accepted: 15 October 2024
First Online: 28 October 2024
Competing interests
: K.M.B. is a member of the advisory board at Matchpoint Therapeutics. A.I.N. and F.Y. receive royalties from the University of Michigan for the sale of MSFragger and IonQuant software licenses to commercial entities. All license transactions are managed by the University of Michigan Innovation Partnerships office, and all proceeds are subject to university technology transfer policy. The remaining authors declare no competing interests.
